# Bioengineered Tricomposite Hydrogel Enhances Chondrogenic Phenotype and Hyaline Matrix Formation in Human Chondrocytes

**Authors:** Antonio Rojas-Murillo, David Andrés de la Garza-Kalife, Jorge Lara-Arias, Héctor Leija-Gutiérrez, Rodolfo Franco-Márquez, Diana Laura Morales-Wong, Félix Vilchez-Cavazos, Elsa Nancy Garza-Treviño, Mario Simental-Mendía

PMC · DOI: 10.3390/gels12010035 · 2025-12-31

## TL;DR

A new hydrogel made from fibrin, cartilage, and amniotic membrane matrices supports cartilage cell growth and matrix formation better than fibrin alone.

## Contribution

A tricomposite hydrogel combining dACM and dAMM with fibrin is introduced to enhance chondrocyte performance.

## Key findings

- The tricomposite hydrogel showed high cell viability (~99%) and supported significant cell expansion (~250% by day 28).
- It increased chondrogenic gene expression (e.g., SOX9 >3-fold) and reduced off-target genes like RUNX2 and COL1A2.
- Histology confirmed proteoglycan-rich matrix and strong type II collagen and aggrecan production.

## Abstract

Fibrin hydrogels are biocompatible but often lack instructive cues needed to sustain chondrocyte phenotype and cartilage-like matrix formation; therefore, we investigated whether a tricomposite fibrin hydrogel incorporating decellularized articular cartilage matrix (dACM) and decellularized amniotic membrane matrix (dAMM) enhances human articular chondrocyte performance in vitro. Human articular chondrocytes were encapsulated in tricomposite or fibrin-only hydrogels and cultured for 28 days, evaluating degradation kinetics, viability and cell density, histological remodeling (H&E, Masson’s trichrome, Safranin O), immunohistochemistry for type II collagen, aggrecan, and type I collagen, and qPCR of SOX9, COL2A1, ACAN, RUNX2, COL1A2, and COL10A1. The tricomposite remained cytocompatible (~99% viability), supported marked cell expansion (~250% by day 28), and degraded more slowly than fibrin controls. It increased chondrogenic gene expression (SOX9 >3-fold vs. control by day 28; sustained COL2A1 at 1.5–2-fold; early ACAN at 3–5-fold) while attenuating off-target transcriptional programs (RUNX2 ~50% of control, reduced COL1A2, and negligible COL10A1). Consistently, histology showed progressive lacuna-like morphology and proteoglycan-rich matrix accumulation, accompanied by strong type II collagen and aggrecan immunoreactivity and reduced type I collagen. Overall, adding dACM and dAMM to fibrin improved hydrogel biofunctionality and promoted hyaline-like extracellular matrix assembly, supporting further evaluation of this cell-instructive platform for focal articular cartilage repair.

## Linked entities

- **Genes:** SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662], COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280], ACAN (aggrecan) [NCBI Gene 176], RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860], COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278], COL10A1 (collagen type X alpha 1 chain) [NCBI Gene 1300]
- **Proteins:** acan.L (aggrecan L homeolog)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** COL10A1 (collagen type X alpha 1 chain) [NCBI Gene 1300], RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}
- **Chemicals:** Masson's trichrome (-), H&amp;E (MESH:D006371), Safranin O (MESH:C009195)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12841122/full.md

---
Source: https://tomesphere.com/paper/PMC12841122